Cancer immunotherapy: accomplishments to date and future promise.
暂无分享,去创建一个
Pranela Rameshwar | P. Rameshwar | K. Helmy | Shyam A. Patel | George R. Nahas | Karim Y Helmy | Shyam A Patel | George R Nahas
[1] G. Bepler,et al. Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[2] G. Coukos,et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). , 2011, Cancer research.
[3] L. Old. Immunotherapy for cancer. , 1996, Scientific American.
[4] M. Martelli,et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.
[5] D. Gabrilovich,et al. Myeloid-derived suppressor cells. , 2007, Advances in experimental medicine and biology.
[6] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.
[7] R. Prehn,et al. Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.
[8] S. Sleijfer,et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Eggermont,et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Herberman,et al. Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells. , 1973, Journal of immunology.
[11] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[12] R. Kiessling,et al. „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype , 1975, European journal of immunology.
[13] W. Zou. Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.
[14] O. Finn,et al. Tumor antigens and tumor antigen discovery. , 2005, Cancer treatment and research.
[15] Gang Wang,et al. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.
[16] H. Kolb. Graft-versus-leukemia effects of transplantation and donor lymphocytes. , 2008, Blood.
[17] D. Lubaroff. Prostate cancer vaccines in clinical trials , 2012, Expert review of vaccines.
[18] N. Senzer,et al. Oncolytic viruses for induction of anti-tumor immunity. , 2012, Current pharmaceutical biotechnology.
[19] W. Coley. The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .
[20] Adrian P Gee,et al. Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.
[21] Zlatko Trajanoski,et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Neri,et al. Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends , 2011, Clinical Cancer Research.
[23] M. Burnet. Cancer—A Biological Approach , 1957, British medical journal.
[24] J. Yewdell,et al. Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.
[25] G. Rabinovich,et al. Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.
[26] T. Treasure,et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Baccarani,et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.
[28] S. Loi,et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[29] S. Steinberg,et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.
[30] Drew A. Torigian,et al. CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.
[31] F. Hagemeister,et al. Denileukin diftitox: a novel immunotoxin , 2009, Expert opinion on biological therapy.
[32] F. Marincola,et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.
[33] F. Shanahan,et al. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-β expression , 2003, British Journal of Cancer.
[34] Beverly A. Teicher,et al. Transforming Growth Factor-β and the Immune Response to Malignant Disease , 2007, Clinical Cancer Research.
[35] A. Ashkar,et al. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity , 2011, Cancer Gene Therapy.
[36] Jinjuan Wang,et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.
[37] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[38] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[39] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[40] M. Merino,et al. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[41] F. Marincola,et al. Prediction of response to anticancer immunotherapy using gene signatures. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] H. Stam,et al. The spontaneous regression of cancer. A review of cases from 1900 to 1987. , 1990, Acta oncologica.
[43] Nina Bhardwaj,et al. Consequences of cell death: exposure to necrotic tumor cells , 2000 .
[44] Y. Nishikawa,et al. Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer. , 2011, Hepato-gastroenterology.
[45] Z. Trajanoski,et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.
[46] S. Latour,et al. Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells , 2009, Nature Immunology.
[47] F. Errington,et al. Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy? , 2008, Clinical medicine. Oncology.
[48] O. Finn,et al. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] T. Whiteside,et al. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. , 2007, Cancer research.
[50] C. Klebanoff,et al. Paths to stemness: building the ultimate antitumour T cell , 2012, Nature Reviews Cancer.
[51] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[52] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[53] H. Ljunggren,et al. Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.
[54] J. Friedberg,et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. , 2009, Blood.
[55] T. Whiteside,et al. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment , 2007, Cancer Immunology, Immunotherapy.
[56] Steven A. Rosenberg,et al. Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.
[57] S. Rosenberg,et al. Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression , 2011, Clinical Cancer Research.
[58] M. Dhodapkar,et al. Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells , 2002, The Journal of experimental medicine.
[59] S. Rosenberg,et al. Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.
[60] A. Enk,et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro , 2007, International journal of cancer.
[61] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[62] A. Friedman,et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.
[63] Hans Schreiber,et al. Specificity in cancer immunotherapy. , 2008, Seminars in immunology.
[64] P. Murawa,et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.
[65] I. Weissman,et al. Programmed cell removal: a new obstacle in the road to developing cancer , 2011, Nature Reviews Cancer.
[66] R. Sims. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. , 2012, Vaccine.
[67] Louis M. Weiner,et al. Antibody-Based Immunotherapy of Cancer , 2012, Cell.
[68] D. Munn,et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.
[69] Ximing J. Yang,et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. , 2005, Cancer research.
[70] S. Geary,et al. Prostate cancer vaccines , 2013, Oncoimmunology.
[71] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[72] C. Vajdic,et al. Cancer incidence and risk factors after solid organ transplantation , 2009, International journal of cancer.
[73] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[74] G. Coukos,et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.
[75] A. Oseroff,et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] A. Chang,et al. Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression , 2011, Clinical Cancer Research.
[77] Rui-Ru Ji,et al. An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.
[78] T. Braun,et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] E. Jaffee,et al. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. , 2005, Cancer research.
[80] T. Waldmann,et al. Immunotherapy: past, present and future , 2003, Nature Medicine.
[81] Ash A. Alizadeh,et al. CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.
[82] J. Rommelaere,et al. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment , 2012, Cancer Immunology, Immunotherapy.
[83] A. Eggermont. Can immuno-oncology offer a truly pan-tumour approach to therapy? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[84] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[85] J. Kirkwood,et al. Next generation of immunotherapy for melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] S. Rosenberg,et al. T-cell therapy at the threshold , 2012, Nature Biotechnology.
[87] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[88] A. Órfão,et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. , 2006, Journal of the National Cancer Institute.
[89] B. Shalmon,et al. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.
[90] R. Patt,et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[91] G. Prendergast,et al. Indoleamine 2,3-dioxygenase in immune suppression and cancer. , 2007, Current cancer drug targets.
[92] S. Rosenberg,et al. Prevention of Interleukin-2 Withdrawal-Induced Apoptosis in Lymphocytes Retrovirally Cotransduced With Genes Encoding an Antitumor T-cell Receptor and an Antiapoptotic Protein , 2010, Journal of immunotherapy.
[93] A. Lawson,et al. Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain , 2004, The Journal of Immunology.
[94] V. Grdzelishvili,et al. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. , 2012, The Journal of general virology.
[95] Michel Sadelain,et al. The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.
[96] B. Shalmon,et al. Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy , 2011, Journal of immunotherapy.
[97] L. Zitvogel,et al. Trial Watch , 2012, Oncoimmunology.
[98] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[99] R. Kiessling. NATURAL KILLER CELLS IN THE MOUSE , 1976 .
[100] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] William B. Colev. I. The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1893 .
[102] Henrik Schmidt,et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma , 2011, Journal of Translational Medicine.
[103] M. Slovak,et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[104] M. Brenner,et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.
[105] J. Wolchok,et al. Antibody therapy of cancer , 2012, Nature Reviews Cancer.
[106] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[107] S. Rosenberg,et al. Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor Activity , 2001, The Journal of Immunology.
[108] Bart Spiessens,et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] Eric Vivier,et al. Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.
[110] M. Peshwa,et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. , 2001, Cancer journal.
[111] W. Burns,et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. , 2011, Blood.
[112] Z. Eshhar,et al. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[113] S. Rosenberg,et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.
[114] S. Rosenberg,et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.
[115] M. Essand,et al. Genetically engineered T cells for the treatment of cancer , 2013, Journal of internal medicine.
[116] R. Figlin,et al. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[117] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[118] R. Herberman,et al. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells , 1975, International journal of cancer.